title: Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization.
abstract: The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.
authors.affiliation: Department of Medicine Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA.
authors.forename: Tyler J
authors.initials: TJ
authors.lastname: Gluckman
authors.forename: Jodi B
authors.initials: JB
authors.lastname: Segal
authors.forename: Natalie L
authors.initials: NL
authors.lastname: Fredde
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Saland
authors.forename: Jayesh T
authors.initials: JT
authors.lastname: Jani
authors.forename: Jeanine M
authors.initials: JM
authors.lastname: Walenga
authors.forename: M Margaret
authors.initials: MM
authors.lastname: Prechel
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Citro
authors.forename: David A
authors.initials: DA
authors.lastname: Zidar
authors.forename: Emily
authors.initials: E
authors.lastname: Fox
authors.forename: Steven P
authors.initials: SP
authors.lastname: Schulman
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Kickler
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Rade
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology*; D003327:Coronary Disease / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007105:Immune Complex Diseases / Q000139:chemically induced / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D015539:Platelet Activation / Q000187:drug effects / Q000276:immunology; D010978:Platelet Factor 4 / Q000276:immunology*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced / Q000175:diagnosis / Q000276:immunology / Q000401:mortality; D012008:Recurrence; D012307:Risk Factors; D012701:Serotonin / Q000097:blood; D015996:Survival Rate
chemical_list: D012701:Serotonin; D010978:Platelet Factor 4; D006493:Heparin